A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension

NCT00264212 Phase 4 COMPLETED

To compare the antihypertensive efficacy and tolerability of irbesartan and irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus hydrochlorothiazide in the treatment of isolated systolic hypertension.

Details

Lead sponsor	Sanofi
Phase	Phase 4
Status	COMPLETED
Enrolment	436
Start date	2004-08

Conditions

• Hypertension

Interventions

• irbesartan and irbesartan-hydrochlorothiazide

Primary outcomes

• Change from baseline in office seated SBP at week 12

Countries

Chile, China, Indonesia, Mexico, Philippines, South Korea, Taiwan, Thailand